ByTrending Posts
Could Immix Biopharma’s Strategic Investment by Goose Capital…
Key Highlights: Strategic Investment Signals Confidence in Immix’s Mission Immix Biopharma (Nasdaq: IMMX), a clinical-stage biopharma innovator, has…
Is Novartis’ $1.4 Billion Acquisition of Tourmaline Bio…
Key Highlights A $1.4 Billion Bet on Cardiovascular Innovation Novartis announced its agreement to acquire Tourmaline Bio for…
Could GE HealthCare’s FDA-Cleared Revolution™ Vibe CT System…
Key Highlights Revolutionizing Cardiac Imaging with One-Beat ClarityGE HealthCare’s Revolution Vibe CT system has received U.S. FDA 510(k)…
Could Merck and Daiichi Sankyo’s 48% Response Rate…
Key Highlights Promising Phase 2 Data Signals Breakthrough PotentialResults from the IDeate-Lung01 trial demonstrated compelling clinical activity in…
Could Arrowhead’s $2.2B+ RNAi Collaboration with Novartis Redefine…
Key Highlights Strategic SignificanceFor Arrowhead, the deal represents its largest CNS collaboration to date, validating the TRiM™ platform’s…
Could Servier’s $450M Fragile X Acquisition Redefine Its…
Key Highlights Strategic Fit for ServierThis marks Servier’s first neurology asset acquisition, aligned with its 2030 strategy to…
Will GSK’s Fluviral Supply Strengthen Canada’s Seasonal Flu…
Key Highlights Public Health ImpactAnnual flu vaccination remains the most effective tool to reduce flu-related risks. Vulnerable populations…
Could Takeda’s Landmark Phase 3 Oveporexton Results Redefine…
Key Highlights Clinical Breakthroughs Across EndpointsPatients treated with oveporexton demonstrated marked improvements in excessive daytime sleepiness, with most…
Could Roche’s New Vabysmo Data Redefine Long-Term Care…
Key Highlights Durability Demonstrated in AVONELLE-XRoche presented four-year data from AVONELLE-X at the Euretina 2025 Congress, showing that…
Trending Posts
Latest Stories
BioMarin Announces Agreement to Acquire Amicus Therapeutics in $4.8 Billion Transaction
San Rafael, CA — BioMarin Pharmaceutical Inc. today announced that it has entered into a…
Bristol Myers Squibb Unveils “Mosaic” AI Content Hub in Mumbai, Advancing Tech-Enabled Patient Engagement
Mumbai, India Bristol Myers Squibb (BMS) today announced the launch of Mosaic, a new artificial…
Endpoints Signal Report Finds Nearly Half of Biopharma Professionals Are Heavy AI Users, With Expectations of Major R&D Transformation Ahead
Based on Endpoints Signal Pulse Report | December 2025 A new Signal Pulse Report from…
Chai Discovery Becomes Newest AI Unicorn Following $130 Million Series B Financing
Company valued at $1.3 billion as investors back AI-native drug discovery platform San Francisco, California…
Gallery
